Loading
Please wait while we load your information from QuoteMedia.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
As of July 7, 2025 • 11:31 PM ET
As of July 7, 2025 • 11:31 PM ET
Date/Time | Source | News Release |
---|---|---|
09/23/2022 01:41 AM EDT | SeekingAlpha | OSE Immunotherapeutics SA GAAP EPS of -Euro0.11, revenue of Euro16.05M |
05/27/2021 04:09 PM EDT | SeekingAlpha | Phase 2 trials begin of OSE's vaccine with Bristol's Opdivo in NSCLC |
03/26/2021 02:05 PM EDT | SeekingAlpha | OSE Immunotherapeutics SA reports FY results |
01/18/2021 10:22 AM EST | SeekingAlpha | Trillium Therapeutics: A Potentially Undervalued CD47 Player |
10/05/2018 01:23 PM EDT | SeekingAlpha | OSE Immunotherapeutics Presents At 18th Annual Biotech in Europe Investor Forum - Slideshow |
09/06/2018 12:07 PM EDT | SeekingAlpha | OSE Immunotherapeutics reports 1H results |
07/03/2018 12:00 PM EDT | SeekingAlpha | Targeting CD47: To Eat Or Not To Eat? |
03/28/2018 12:09 PM EDT | SeekingAlpha | OSE Immunotherapeutics reports FY results |
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.